Anti-Cancer Drug Library

Anti-Cancer Drug Library

Anti-Cancer Drug Library

During the past decades, we have witnessed many landmark discoveries and successes in cancer research and therapy, however, cancer is still a major health problem for human beings, and it often physically and emotionally brings pains and difficulties to those living with it. Cancer cells remain undifferentiated (continue to divide, causing more damage, and invading new tissue), lack normal cell signaling responses (loss of contact inhibition and evasion of programmed cell death), contain abnormal changes (genetic abnormalities) in chromatin, have altered energy metabolism, and induce vascularization (ensure a steady supply of oxygen and nutrients).


We carefully select 2,478 anticancer drugs including FDA approved and compounds in clinical trial phases as Anticancer Drug Library that can be used for tumor-related research and anti-tumor drug screening.

All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.

Product Description

  • A unique collection of 2,478 anticancer drugs for high throughput screening (HTS) and high content screening (HCS).
  • Bioactivity and safety profiled in (confirmed by) pre-clinical and clinical settings (research and trials), an effective tool for molecular mechanism of tumorigenesis, and anti-tumor drug repositioning drug discovery.
  • Covers various major targets including PI3K, HDAC, mTOR, CDK, Aurora Kinase, JAK, etc; involved in 15 different cancer research areas, such as lung cancer, breast cancer, leukemia, lymphoma, etc.
  • Detailed compound information with structure, target, activity, IC50 value, and biological activity description.
  • Structurally diverse, medicinally active, and cell permeable.
  • NMR and HPLC validated to ensure high purity and quality.

Library Composition

Anti-Cancer Drug Library Anti-Cancer Drug Library Anti-Cancer Drug Library Anti-Cancer Drug Library